Patient-Reported Outcomes with High-Volume Hemodiafiltration Versus High-Flux Hemodialysis Across Clinical Subgroups
Clinical Journal of the American Society of Nephrology · 30.10.2026
DOI: 10.2215/cjn.0000001253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 30.10.2026. Verfasst von Krister Cromm und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Patient-Centered Outcomes Research (CPCOR), Department of Psychosomatic Medicine, Charité - Universitätsmedizin Berlin, corporate member o….
Abstract (Originalsprache)
Background
High-volume hemodiafiltration (HDF) improves survival and attenuates decline in selected patient-reported outcome (PRO) domains versus high-flux hemodialysis (HD). Whether benefits differ across clinically relevant subgroups remains uncertain.
Methods
We conducted a prespecified subgroup analysis of the multicenter CONVINCE randomized controlled trial comparing high-volume post-dilution HDF (≥23 L/session) with high-flux HD in adults receiving maintenance dialysis. Eight PROMIS domains were assessed quarterly over a median follow-up of 30 months. Linear mixed-effects models evaluated longitudinal PRO changes and treatment-by-subgroup interactions by prespecified baseline characteristics: age, sex, diabetes, cardiovascular disease, dialysis vintage, vascular access type, and residual urine volume. Joint-model sensitivity analyses of all eight longitudinal PROMIS trajectories and time to death assessed informative dropout due to death.
Results
Of 1360 randomized participants, 1211 with baseline and follow-up PRO assessments were included. PRO treatment effects were broadly consistent across prespecified clinical subgroups, without evidence of clinically meaningful heterogeneity. Models adjusted for baseline sociodemographic and clinical characteristics showed nominal treatment-by-subgroup interactions for dialysis vintage and physical function (P = 0.03), age and pain interference (P = 0.02), and dialysis vintage and sleep disturbance (P = 0.04). Joint-model sensitivity analyses accounting for informative dropout due to mortality reproduced the first two interactions and identified nominal interactions for vascular access type and sleep disturbance (P = 0.03) and cardiovascular disease status and cognitive function (P = 0.05). Interactions were modest in magnitude, exploratory, unadjusted for multiple comparisons, and not consistently observed across related PROMIS domains.
Conclusions
This prespecified exploratory subgroup analysis found no convincing evidence of clinically meaningful treatment-effect heterogeneity across baseline characteristics examined. Nominal interactions were unadjusted for multiple comparisons and should be regarded as hypothesis-generating. Findings should not guide selection or exclusion of patients for high-volume HDF based on patient-reported outcomes.
Autor:innen und Institutionen
- Center for Patient-Centered Outcomes Research (CPCOR), Department of Psychosomatic Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin,…
- Global Medical Office, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany.
- Department of Precision and Regenerative Medicine and Ionian Area (Dimepre-J), University of Bari, Italy.
- Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- Medical Scientific Affairs, B. Braun Avitum AG, Melsungen, Germany.
ORCID-Profile: Krister Cromm, Felix Fischer, Giovanni Pellegrino, Robin W M Vernooij, Leili Riazy, Claudia Barth, Michiel L Bots, Bernard Canaud, Andrew Davenport, Jörgen Hegbrant, Mark Woodward
Zitieren
APA
Cromm, K., Fischer, F., Pellegrino, G., Vernooij, R. W. M., Riazy, L., Barth, C., Blankestijn, P. J., Bots, M. L., Canaud, B., Davenport, A., Hegbrant, J., Woodward, M., Rose, M., & Strippoli, G. F. M. (2026). Patient-Reported Outcomes with High-Volume Hemodiafiltration Versus High-Flux Hemodialysis Across Clinical Subgroups. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001253
Vancouver
Cromm K, Fischer F, Pellegrino G, Vernooij RWM, Riazy L, Barth C, et al. Patient-Reported Outcomes with High-Volume Hemodiafiltration Versus High-Flux Hemodialysis Across Clinical Subgroups. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001253
BibTeX
@article{Cromm2026,
author = {Cromm, Krister and Fischer, Felix and Pellegrino, Giovanni and Vernooij, Robin W M and Riazy, Leili and Barth, Claudia and Blankestijn, Peter J and Bots, Michiel L and Canaud, Bernard and Davenport, Andrew and Hegbrant, Jörgen and Woodward, Mark and Rose, Matthias and Strippoli, Giovanni F M},
title = {Patient-Reported Outcomes with High-Volume Hemodiafiltration Versus High-Flux Hemodialysis Across Clinical Subgroups},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000001253}
}
EUVIMED